Searching for Innovative Cancer Therapies in Biotech - Seite 2

Kura Oncology, Inc. (NASDAQ: KURA)

Market Cap: $413.936M, current share price: $14.95 

KURA is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Earlier this month, KURA released favorable results from a Phase 2 trial for its lead product candidate, tipifarnib. They tested their lead product in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck (HNSCC). The Phase 2 trial achieved its primary endpoint prior to the completion of enrollment. Keep an eye out on KURA as they move through trials.

Moleculin Biotech, Inc. (NASDAQ: MBRX)

Market Cap: $48.426M, current share price: $2.39 

MBRX is a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates. Just this week, MBRX announced that the Food and Drug Administration (FDA) has instructed Moleculin it may begin clinical trials of Annamycin in the treatment of relapsed or refractory Acute Myeloid Leukemia (AML). MBRX currently has two preclinical small molecule portfolios in development, one is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient's own immune system the other targets the metabolism of tumors.

ImmunoGen, Inc. (NASDAQ: IMGN)

Market Cap: $858.49M, current share price: $7.65 

IMGN is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. IMGN's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer. It's IMGN's mission to deliver innovative cancer therapies that meaningfully improve the lives of patients.

Endocyte, Inc. (NASDAQ: ECYT)

Market Cap: $265.67M, current share price: $6.21 

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. Endocyte uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The company's agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (PSMA) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.